161599-46-8

• 常用中文名：2',3'-二-O-乙酰基-5'-脱氧-5-氟胞苷
• 常用英文名：2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-D-cytidine
• CAS号：161599-46-8
• 分子式：C₁₃H₁₆FN₃O₆
• 分子量：329.281
• 相关类别： 生物化工 核苷类药物 脱氧核苷酸及其类似物
• 发布时间：2018-11-24 16:16:23
• 更新时间：2026-06-30 10:36:36

名称

• 中文名: 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶
• 英文名: 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine
• 中文别名: 2',3'-二乙酰基-5-氟-5'-脱氧胞苷; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶；卡培他滨杂质D; 2',3'-二-O-乙酰基-5'-脱氧-5-氟胞嘧啶核苷; 2',3'-二-O-乙酰基-5; (2R,3R,4R,5R)-2-(4-氨基-5-氟-2-氧代嘧啶-1(2H)-基)-5-甲基四氢呋喃-3,4-二基二乙酸酯; 5'-脱氧-5-氟胞嘧啶核苷-2',3'-二乙酸酯; 卡培他滨中间体/2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶; 5'-脱氧-二乙酰-5-氟胞苷; 卡培他滨杂质13(卡培他滨杂质C); 2', 3'-二乙酰基-5'-脱氧-5-氟胞苷; 2'.3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞苷; 卡培中间体5; 2',3'-二-O-乙酰基-5'-脱氧-5-氟胞苷2',3'-二-O-乙酰基-5'-脱氧-5-氟胞苷; 5'-脱氧-2',3'-二-O-乙酰基-5-氟胞苷; 5'-脱氧-5'-氟胞苷5'-DEOXY-2',3'-DI-O-ACETYL-5-FLUOROCYTIDINE; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶,10 MM DMSO 溶液; 卡五; 2',3'-二氧-乙酰基-5'-脱氧-5-氟胞苷; 卡培他滨中间体2/2',3'-二-O-乙酰基-5'-脱氧-5-氟胞苷; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶(卡培他滨中间体); 卡培他滨中间体Cap-5; 5'-脱氧-二乙酰-5-氟胞; 2',3'-DI-O-乙酰-5'-脱氧-5-氟胞苷; 2',3'二-O-乙酰基-5'-脱氧-5-氟胞苷; 甲基-氨基甲酸叔丁酯/Tert-butyl methylcbamate; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞苷; 2',3'-二-O-乙酰基-5'-脱氧-5-氟胞啶; 卡培他滨杂质13; 卡培他滨中间体K6; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶(K7); 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶(卡培他滨中间体; 2,3-二-O-乙酰基-5-脱氧-氟胞苷; 卡培他滨中间体4; 2',3'-DI-O-乙酰-5'-脱氧-5-富鲁-D-胞苷; 卡培他滨杂质D; 2',3'-二-O-乙酰基-5'-脱氧-5-氟胞苷 161-8; 卡培他滨中间体2; 卡培他滨杂质C; 2,3-二-O-乙酰基-5-脱氧-5-氟-D-胞啶; 卡培他滨中间体-A-09-I; 市场认可的是中间体3; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶(卡培他滨杂质); 3'-二-O-乙酰基-5'-脱氧-5-氟胞苷; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶苷; 卡培中间体; 2',3'-二-O-乙酰基-5'-脱氧-5-氟胞啶*5; 2',3'-二-O-乙酰基-5'-脱氧-5-氟-D-胞啶2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-D-cytidine
• 英文别名: InterMediate of Capecitabine; 3'-di-O-acetyl-5'-deoxy-5-fulurocytidine; Cytidine,5'-deoxy-5-fluoro-, 2',3'-diacetate; Cytidine, 5'-deoxy-5-fluoro-, 2',3'-diacetate (9CI, ACI); 2',3'-Di-o-acetyl-5-fluoro cytidine; Capecitabine impurity 4/Capecitabine Impurity C/Capecitabine Diacetyl Amino Impurity /2’,3’-Di-O-acetyl-5’-deoxy-5-fluorocytidine; 5'-deoxy - diacetyl -5- fluoro cytidine; (2R,3R,4R,5R)-2-(4-Amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyltetrahydrofuran-3,4-diyl diacetate; Cytidine, 5'-deoxy-5-fluoro-, 2',3'-diacetate; 1-(2,3-Di-O-acetyl-5-deoxy-β-D-ribofuranosyl)-5-fluoro-4-imino-1,4-dihydro-2-pyrimidinol; 5’-Deoxy-5-fluorocytidine 2’,3’-Diacetate; 2 ', 3'-di-O-acetyl -5' - deoxy -5- fluoro-D-cell pyridine; 2,3-diACETATE 5,DEOXY 5,FLUORO CYTIDINE; 2'',3''DiOacetyl5''deoxy5fuluroDcytidine,2'',3'' Di O acetyl 5'' deoxy 5 fuluro D cytidine; Capecitabine IMp.D; 2',3'-DI-O-ACETYL-5'-DEOXY-5-FULUROD-CYTIDI; T6NVNJ DZ EF A- BT5OTJ COV1 DOV1 E1 &&Ribo-β-D Form; 2',3'-Di-O-acetyl-5'-deoxy-5-fuluro-D-cytidine //BP; 5'-deoxy-5-fluoro-Cytidine 2',3'-diacetate (9CI ACI); 2',3'-Di-O-carbonyl-5'-deoxy-5-fluorocytidine; Capecitabine Impurity M(Capecitabine Impurity C); uorocytidine; 2',3'-Di-O-acetyl-5'-deoxy-5-fuluro-D-cytidine; Capecitabin iMpurity D; Capecitabine-2; 2',3'-Di-O-acetyl-5'-deoxy-5-F-Cytidine; 2'''',3''''-Di-O-acetyl-5''''-deoxy-5-fuluro-D-cytidine; (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyriMidin-1(2H)-yl)-5-Methyltetrahydrofuran-3,4-diyl diacetate; 2,3-Di-O-Acetyl-5-Deoxy-5-Fuluro-D-Cytidine; 2',3'-Di-O-acetyL; 2',3'-DI-O-ACETYL-5'-DEOXY-5-FLUOROCYTIDIN; 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine; 5'-Deoxy-5-fluoro-cytidine 2',3'-Diacetate; 2',3'-Diacetoxyl-5'-deoxy-5-flurocytidine; (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2-fluoro-5-methyltetrahydrofuran-3,4-diyl diacetate; 2'''',3''''-Di-O-acetyl-5''''-deoxy-5-fuluro-D-cytidine, 10 mM in DMSO; 2,3-DI-O-ACETYL-5-DEOXY-5-FULURO-D-CYTIDINE; 2',3'-Di-O-acetyl-5'-deoxy-5-flouro-D-cytidine; 2',3'-Di-O-acetyl-5'-deoxy-5-fulurocytdine; 2,3-Di-O-acetyl-5-deoxy-5-fluoro-D-cytidine [CAP5]; 1-(2,3-Di-O-acetyl-5-deoxy-beta-D-ribofuranosyl)-4-amino-5-fluoropyrimidin-2(1H)-one; Capecitabine Diacetyl Amino Imp; Capecitabine Impurity M; 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine; Capecitabine Impurity 13(Capecitabine Impurity C); Capecitabine Diacetyl Amino Impurity; 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (Capecitabine Impurity); Capecitabine Impurity C; (2R,3R,4S,5R)-2-(4-Amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyltetrahydrofuran-3,4-diyl di; Capecitabine Impurity D; (2R,3R,4S,5R)-4-(acetyloxy)-2-(4-amino-5-fluoro-2-oxo-1,2-dihydropyriMidin-1-yl)-5-Methyloxolan-3-yl acetate; 2'',3''-Di-O-acetyl-5''-deoxy-5-fuluro-D-cytidine; [(2R,3R,4R,5R)-4-acetyloxy-5-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate; 5'-deoxy-5-fL; 2',3'-di-O-acetyl-5'-deoxy-5-fulurocytidine; [(2R,3R,4R,5R)-4-acetoxy-5-(4-amino-5-fluoro-2-oxo-pyrimidin-1-yl)-2-methyl-tetrahydrofuran-3-yl] acetate

物化性质

• 密度: 1.6±0.1 g/cm3
• 沸点: 427.4±55.0 °C at 760 mmHg
• 熔点: 196-198?C
• 分子式: C₁₃H₁₆FN₃O₆
• 分子量: 329.281
• 闪点: 212.3±31.5 °C
• 精确质量: 329.102325
• PSA: 122.74000
• LogP: 0.24
• 外观性状: 固体;White to Almost white powder to crystal
• 蒸汽压: 0.0±1.0 mmHg at 25°C
• 折射率: 1.609
• 储存条件: -20°C Freezer
• 水溶解性: 可溶于：甲醇

安全

• 危害码 (欧洲): Xi
• 海关编码: 2934999090

合成路线

2022-85-7 27821-07-4 ~82% 161599-46-8

文献：ScinoPharm Taiwan Ltd. Patent: US2011/21769 A1, 2011 ; Location in patent: Page/Page column 3; 5 ;

2022-85-7 37076-71-4 ~% 161599-46-8

文献：WO2010/65586 A2, ; Page/Page column 23 ;

37076-71-4 41108-04-7 ~% 161599-46-8

文献：WO2010/85377 A2, ; Page/Page column 54 ; WO 2010/085377 A2

108-24-7 66335-38-4 ~% 161599-46-8

文献：WO2009/42613 A1, ; Page/Page column 56 ;

66335-38-4 ~% 161599-46-8

文献：US5472949 A1, ;

880633-97-6 ~% 161599-46-8

文献：WO2006/32921 A1, ; Page/Page column 25 ;

上下游产品

上游产品  7
2022-85-7 27821-07-4 37076-71-4 41108-04-7
108-24-7 66335-38-4 880633-97-6
下游产品  5
66335-38-4 162204-20-8 124012-42-6 162204-22-0
154361-50-9

海关

海关编码	2934999090
中文概述	2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%